Hodgkin's disease.
Significant progress has been made over the past decade in the classification, diagnosis, staging, prognosis, and treatment of Hodgkin's disease (HD). A new classification system has recognized differences in the natural history of certain subtypes. The introduction of positron emission tomography has improved the accuracy of non-invasive staging. New prognostic indices have led to the development of risk-adapted treatment strategies. The serious long-term side effects of extended-field radiotherapy have prompted the increasing use of chemotherapy in conjunction with limited radiotherapy for early-stage patients. Combination chemotherapy remains the treatment of choice for advanced HD, and new dose-intense regimens appear to have improved activity. Patients who relapse now have a more favorable prognosis with the availability of active salvage regimens, autologous stem cell transplantation, and novel biologic agents.
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Bradley C
BC
Ekstrand
Sandra J
SJ
Horning
D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000145:classification / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D016879:Salvage Therapy